Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
| dc.contributor.author | Fizazi, K | |
| dc.contributor.author | Massard, C | |
| dc.contributor.author | Bono, P | |
| dc.contributor.author | Jones, R | |
| dc.contributor.author | Kataja, V | |
| dc.contributor.author | James, N | |
| dc.contributor.author | Garcia, J | |
| dc.contributor.author | Protheroe, A | |
| dc.contributor.author | Tammela, T | |
| dc.contributor.author | Elliott, Tony | |
| dc.contributor.author | Mattila, L | |
| dc.contributor.author | Aspegren, J | |
| dc.contributor.author | Vuorela, A | |
| dc.contributor.author | Langmuir, P | |
| dc.contributor.author | Mustonen, M | |
| dc.date.accessioned | 2014-07-08T13:59:00Z | |
| dc.date.available | 2014-07-08T13:59:00Z | |
| dc.date.issued | 2014-06-25 | |
| dc.identifier.citation | Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. 2014: Lancet Oncol. | en |
| dc.identifier.issn | 1474-5488 | |
| dc.identifier.pmid | 24974051 | |
| dc.identifier.doi | 10.1016/S1470-2045(14)70240-2 | |
| dc.identifier.uri | http://hdl.handle.net/10541/322578 | |
| dc.description.abstract | ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. This trial assessed ODM-201's safety, pharmacokinetics, and activity in men with metastatic castration-resistant prostate cancer. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to The lancet oncology | en |
| dc.title | Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. | en |
| dc.type | Article | en |
| dc.contributor.department | Institut Gustave Roussy, University of Paris Sud, Villejuif, France. | en |
| dc.identifier.journal | The Lancet Oncology | en |
| html.description.abstract | ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. This trial assessed ODM-201's safety, pharmacokinetics, and activity in men with metastatic castration-resistant prostate cancer. |